{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:53:29Z","timestamp":1768838009895,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T00:00:00Z","timestamp":1637366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T00:00:00Z","timestamp":1637366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s11255-021-03061-9","type":"journal-article","created":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T03:02:40Z","timestamp":1637377360000},"page":"1713-1723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anti-phospholipase A2 receptor antibody screening in nephrotic syndrome may identify a distinct subset of patients with primary membranous nephropathy"],"prefix":"10.1007","volume":"54","author":[{"given":"Roxana","family":"Jurubi\u021b\u0103","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4796-4950","authenticated-orcid":false,"given":"Bogdan","family":"Obri\u0219c\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camelia","family":"Achim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Micu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Sorohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raluca","family":"Bobeic\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Vornicu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"G\u0103man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"C\u0103pu\u0219\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"\u0218tefan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Via\u0219u","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Mircescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gener","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,20]]},"reference":[{"key":"3061_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/249740","volume":"2015","author":"B Obrisca","year":"2015","unstructured":"Obrisca B, Ismail G, Jurubita R, Baston C, Andronesi A, Mircescu G (2015) Antiphospholipase A2 receptor autoantibodies: a step forward in the management of primary membranous nephropathy. Biomed Res Int 2015:1\u20138","journal-title":"Biomed Res Int"},{"issue":"4","key":"3061_CR2","doi-asserted-by":"publisher","first-page":"614","DOI":"10.2215\/CJN.10871016","volume":"12","author":"MM O\u2019Shaughnessy","year":"2017","unstructured":"O\u2019Shaughnessy MM, Hogan SL, Poulton CJ, Falk RJ, Singh HK, Nickeleit V et al (2017) Temporal and demographic trends in glomerular disease epidemiology in the southeastern United States, 1986\u20132015. Clin J Am Soc Nephrol 12(4):614\u2013623","journal-title":"Clin J Am Soc Nephrol"},{"key":"3061_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck Jr","year":"2009","unstructured":"Beck LH Jr, Bonegio RGB, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11\u201321","journal-title":"N Engl J Med"},{"issue":"2","key":"3061_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1681\/ASN.2020071082","volume":"32","author":"S Sethi","year":"2021","unstructured":"Sethi S (2021) New \u2018antigens\u2019 in membranous nephropathy. J Am Soc Nephrol 32(2):268\u2013278","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3061_CR5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1681\/ASN.2016070776","volume":"28","author":"AS De Vriese","year":"2017","unstructured":"De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC (2017) A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol 28(2):421\u2013430","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"3061_CR6","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.kint.2019.10.022","volume":"97","author":"C Meyer-Schwesinger","year":"2020","unstructured":"Meyer-Schwesinger C, Tomas NM, Dehde S, Seifert L, Hermans-Borgmeyer I, Wiech T et al (2020) A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients. Kidney Int 97(5):913\u2013919","journal-title":"Kidney Int"},{"issue":"10","key":"3061_CR7","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1681\/ASN.2014070640","volume":"26","author":"P Ruggenenti","year":"2015","unstructured":"Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pell\u00e9 T, Gaspari F et al (2015) Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 26(10):2545\u20132558","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3061_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","volume":"28","author":"K Dahan","year":"2017","unstructured":"Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L et al (2017) Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol 28(1):348\u2013358","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"3061_CR9","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1159\/000494662","volume":"48","author":"Z Qu","year":"2018","unstructured":"Qu Z, Zhang MF, Cui Z, Wang J, Wang M, Zhang YM et al (2018) Antibodies against M-type phospholipase A2 receptor may predict treatment response and outcome in membranous nephropathy. Am J Nephrol 48(6):438\u2013446","journal-title":"Am J Nephrol"},{"issue":"1","key":"3061_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/ckj\/sfy005","volume":"12","author":"LM Rodas","year":"2019","unstructured":"Rodas LM, Matas-Garc\u00eda A, Barros X, Blasco M, Vi\u00f1as O, Llobell A et al (2019) Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy. Clin Kidney J 12(1):36\u201341","journal-title":"Clin Kidney J"},{"issue":"1","key":"3061_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1681\/ASN.2019050538","volume":"31","author":"PD Burbelo","year":"2020","unstructured":"Burbelo PD, Joshi M, Chaturvedi A, Little DJ, Thurlow JS, Waldman M et al (2020) Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy. J Am Soc Nephrol 31(1):208\u2013217","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3061_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1053\/j.ajkd.2020.10.009","volume":"77","author":"L Alsharhan","year":"2021","unstructured":"Alsharhan L, Beck LH Jr (2021) Membranous nephropathy: core curriculum 2021. Am J Kidney Dis 77(3):440\u2013453","journal-title":"Am J Kidney Dis"},{"key":"3061_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00101","author":"W Li","year":"2018","unstructured":"Li W, Zhao Y, Fu P (2018) Diagnostic test accuracy of serum anti-PLA2R autoantibodies and glomerular PLA2R antigen for diagnosing idiopathic membranous nephropathy: an updated meta-analysis. Front Med. https:\/\/doi.org\/10.3389\/fmed.2018.00101","journal-title":"Front Med"},{"issue":"2","key":"3061_CR14","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.kint.2018.10.021","volume":"95","author":"SA Bobart","year":"2019","unstructured":"Bobart SA, De Vriese AS, Pawar AS, Zand L, Sethi S, Giesen C et al (2019) Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int 95(2):429\u2013438","journal-title":"Kidney Int"},{"issue":"24","key":"3061_CR15","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","volume":"371","author":"NM Tomas","year":"2014","unstructured":"Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G et al (2014) Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 371(24):2277\u20132287","journal-title":"N Engl J Med"},{"issue":"6","key":"3061_CR16","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1681\/ASN.2018080852","volume":"30","author":"S Sethi","year":"2019","unstructured":"Sethi S, Madden BJ, Debiec H, Cristine Charlesworth M, Gross L, Ravindran A et al (2019) Exostosin 1\/exostosin 2\u2013associated membranous nephropathy. J Am Soc Nephrol 30(6):1123\u20131136","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3061_CR17","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","volume":"99","author":"T Caza","year":"2021","unstructured":"Caza T, Hassen S, Dvanajscak Z, Kuperman M, Edmondson R, Herzog C et al (2021) NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int 99(4):967\u2013976","journal-title":"Kidney Int"},{"issue":"6","key":"3061_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0158154","volume":"11","author":"K Hihara","year":"2016","unstructured":"Hihara K, Iyoda M, Tachibana S, Iseri K, Saito T, Yamamoto Y et al (2016) Anti-phospholipase A2 receptor (PLA2R) antibody and glomerular PLA2R expression in Japanese patients with membranous nephropathy. PLoS ONE 11(6):1\u201312","journal-title":"PLoS ONE"},{"issue":"3","key":"3061_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.pathol.2016.02.001","volume":"48","author":"L Ong","year":"2016","unstructured":"Ong L, Silvestrini R, Chapman J, Fulcher DA, Lin MW (2016) Validation of a phospholipase A2 receptor antibody ELISA in an Australian cohort with membranous glomerulonephritis. Pathology 48(3):242\u2013246","journal-title":"Pathology"},{"issue":"6","key":"3061_CR20","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s11255-016-1263-6","volume":"48","author":"Y Dou","year":"2016","unstructured":"Dou Y, Zhang L, Liu D, Wang C, Quan S, Ma S et al (2016) The accuracy of the anti-phospholipase A2 receptor antibody in the diagnosis of idiopathic membranous nephropathy: a comparison of different cutoff values as measured by the ELISA method. Int Urol Nephrol 48(6):845\u2013849","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"3061_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/nep.12624","volume":"21","author":"PA Hill","year":"2016","unstructured":"Hill PA, McRae JL, Dwyer KM (2016) PLA2R and membranous nephropathy: a 3 year prospective Australian study. Nephrology 21(5):397\u2013403","journal-title":"Nephrology"},{"key":"3061_CR22","first-page":"24","volume":"96","author":"L Pang","year":"2017","unstructured":"Pang L, Zhang AM, Li HX, Du JL, Jiao LL, Duan N et al (2017) Serum anti-PLA2R antibody and glomerular PLA2R deposition in Chinese patients with membranous nephropathy: a cross-sectional study. Medicine 96:24","journal-title":"Medicine"},{"issue":"6","key":"3061_CR23","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1681\/ASN.2010090967","volume":"22","author":"W Qin","year":"2011","unstructured":"Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K et al (2011) Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 22(6):1137\u20131143","journal-title":"J Am Soc Nephrol"},{"issue":"4\u20135","key":"3061_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000431331","volume":"41","author":"Q Xie","year":"2015","unstructured":"Xie Q, Li Y, Xue J, Xiong Z, Wang L, Sun Z et al (2015) Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy. Am J Nephrol 41(4\u20135):345\u2013353","journal-title":"Am J Nephrol"},{"issue":"5","key":"3061_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/modpathol.2012.207","volume":"26","author":"CP Larsen","year":"2013","unstructured":"Larsen CP, Messias NC, Silva FG, Messias E, Walker PD (2013) Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 26(5):709\u2013715","journal-title":"Mod Pathol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-021-03061-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-021-03061-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-021-03061-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T13:28:36Z","timestamp":1654781316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-021-03061-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,20]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["3061"],"URL":"https:\/\/doi.org\/10.1007\/s11255-021-03061-9","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,20]]},"assertion":[{"value":"22 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted with the provisions of the Declaration of Helsinki and the protocol was approved by the local ethics committee (The Ethics Council of Fundeni Clinical Institute, Registration number: 8851).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}